Diabetic Foot Consortium - Biomarker Meeting
Diabetic foot ulcers (DFUs) are a common complication of diabetes and lead to about 100,000 lower extremity amputations per year in America. Treatment for a DFU is costly, protracted, and, for many individuals, ineffective. The development of new therapies for diabetic wound healing is fraught with challenges, one of which is the lack of biomarkers to predict healing. The goal of the Diabetic Foot Consortium (DFC) is to validate biomarkers for DFUs through a network of clinical and biomarker measurement sites. The purpose of this meeting is to solicit biomarker proposals that could be studied by the DFC.
The DFC consists of three components:
- Clinical sites for the DFC will be selected and funded through the Funding Opportunity Announcement DK-17-014, which describes in detail the organization and activities of the DFC. Patient interactions will take place only at the clinical sites.
- Biomarker measurement sites will receive biosamples and patient data from the clinical sites and will measure the biomarker in the biosample and analyze the results. For biomarkers that involve bedside measurements, such as imaging, the sites will receive the data and analyze the results.
- A data coordinating center (DCC) will coordinate the data collection and statistical analysis. A Funding Opportunity Announcement for the DCC will be released in the future.
October 8, 2018